These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 20308688)

  • 1. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
    Nardin R
    Neurology; 2010 Mar; 74(12):1007; author reply 1007-8. PubMed ID: 20308688
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecule of the month. Telcagepant.
    Drug News Perspect; 2009 Mar; 22(2):115. PubMed ID: 19330169
    [No Abstract]   [Full Text] [Related]  

  • 3. Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.
    Tfelt-Hansen P
    Headache; 2011 Jan; 51(1):118-23. PubMed ID: 21070229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
    Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
    Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis.
    Cui XP; Ye JX; Lin H; Mu JS; Lin M
    Pain Pract; 2015 Feb; 15(2):124-31. PubMed ID: 24382126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine.
    Tepper SJ; Cleves C
    Curr Opin Investig Drugs; 2009 Jul; 10(7):711-20. PubMed ID: 19579177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.
    Ho TW; Ferrari MD; Dodick DW; Galet V; Kost J; Fan X; Leibensperger H; Froman S; Assaid C; Lines C; Koppen H; Winner PK
    Lancet; 2008 Dec; 372(9656):2115-23. PubMed ID: 19036425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease.
    Ho TW; Ho AP; Chaitman BR; Johnson C; Mathew NT; Kost J; Fan X; Aurora SK; Brandes JL; Fei K; Beebe L; Lines C; Krucoff MW
    Headache; 2012 Feb; 52(2):224-35. PubMed ID: 22221076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate.
    Edvinsson L; Linde M
    Lancet; 2010 Aug; 376(9741):645-55. PubMed ID: 20416945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention.
    Ho TW; Connor KM; Zhang Y; Pearlman E; Koppenhaver J; Fan X; Lines C; Edvinsson L; Goadsby PJ; Michelson D
    Neurology; 2014 Sep; 83(11):958-66. PubMed ID: 25107879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimigraine efficacy of telcagepant based on patient's historical triptan response.
    Ho TW; Olesen J; Dodick DW; Kost J; Lines C; Ferrari MD
    Headache; 2011 Jan; 51(1):64-72. PubMed ID: 21054362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, controlled trial of telcagepant over four migraine attacks.
    Ho AP; Dahlöf CG; Silberstein SD; Saper JR; Ashina M; Kost JT; Froman S; Leibensperger H; Lines CR; Ho TW
    Cephalalgia; 2010 Dec; 30(12):1443-57. PubMed ID: 20974601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGRP-receptor antagonism in migraine treatment.
    Edvinsson L
    Lancet; 2008 Dec; 372(9656):2089-90. PubMed ID: 19036426
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine.
    Ho TW; Ho AP; Ge YJ; Assaid C; Gottwald R; MacGregor EA; Mannix LK; van Oosterhout WP; Koppenhaver J; Lines C; Ferrari MD; Michelson D
    Cephalalgia; 2016 Feb; 36(2):148-61. PubMed ID: 25926620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan.
    Dodick DW; Kost J; Assaid C; Lines C; Ho TW
    Cephalalgia; 2011 Feb; 31(3):296-300. PubMed ID: 20937606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine: Telcagepant provides new hope for people with migraine.
    Edvinsson L
    Nat Rev Neurol; 2009 May; 5(5):240-2. PubMed ID: 19488079
    [No Abstract]   [Full Text] [Related]  

  • 17. A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina.
    Chaitman BR; Ho AP; Behm MO; Rowe JF; Palcza JS; Laethem T; Heirman I; Panebianco DL; Kobalava Z; Martsevich SY; Free AL; Bittar N; Chrysant SG; Ho TW; Chodakewitz JA; Murphy MG; Blanchard RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):459-66. PubMed ID: 22278333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974).
    Hopkins CR
    ACS Chem Neurosci; 2011 Jul; 2(7):334-5. PubMed ID: 22816019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CGRP antagonists: novel concept for treatment of migraine].
    Nieber K
    Med Monatsschr Pharm; 2009 May; 32(5):182-5. PubMed ID: 19469188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eager for better migraine therapies: keep your (telcage)PANTs on.
    Lipton RB; Sandor PS
    Neurology; 2014 Sep; 83(11):954-5. PubMed ID: 25107883
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.